Mon, Mar 2, 2015, 9:02 AM EST - U.S. Markets open in 28 mins.


% | $
Quotes you view appear here for quick access.

Ariad Pharmaceuticals Inc. Message Board

simon_tymplar 29 posts  |  Last Activity: Feb 19, 2015 3:40 PM Member since: Jun 1, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • simon_tymplar by simon_tymplar Feb 19, 2015 3:40 PM Flag

    Again. The mm's look at the earnings report and they know that Harvey will use whatever good might come Ariad's way to simply dilute shares at the most inopportune time and add another couple of his buddies as vice presidents of Ariad. Meanwhile the huddled masses who stretch out their hands for a crust of bread are instead given the back of the hand and told to scram. Actually they're told to just hang on until 2018 when things will finally be good for them.

    Releasing a statement that someone or some entity wants to see a change a the top of Ariad can only carry the day for so long. This will finally lose all steam from that announcement and everything will return to status quo which is, for this company - one of the most miserable stocks trading on the stock exchange. Not even good for a swing trade anymore. Pitiful.

    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Feb 18, 2015 2:50 PM Flag

    Ariad share price should drop at least .30 following earnings report in a.m. Probably a good short right here but I will remain on the sidelines for now. Better shorting opportunity ahead.

    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Feb 13, 2015 1:29 PM Flag

    Harvey was not blind sided. He has been expecting this for awhile and preparing his defenses. He will put up one hell of a fight and will not relinquish control easily. If Denner loses the fight he will cash in his chips and move on as the share price plunges. Harvey will give a news conference and talk about how excited he is for the future of Ariad and how they hope to achieve profitability in 2018. Ugh. Hard to stomach. His cronies, many of whom he has made vice presidents of Ariad are pressuring him to keep the gravy train rolling. It'll be interesting to see what happens. I covered my short position this morning and will be warching for a chance to get back in on the short side at the first glimmer that Denner is losing the battle for control.

  • simon_tymplar by simon_tymplar Feb 12, 2015 3:57 PM Flag

    are just falling for the man's rope-a-dope strategy which he has used successfully for 23 years. There's nothing he's presenting which will move the stock up in the near term. It will probably drop instead as most have caught on to his tomorrow and tomorrow and tomorrow strategy. DEAD MONEY.

    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Feb 12, 2015 12:59 PM Flag

    Until 2018. Then it will REALLY plunge, sub $2.00 per share. Thanks Harvey Berger.

    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Feb 11, 2015 1:59 PM Flag

    Just don't pull for this corrupt company. If you do you're not going to win anyway. There is a ton of bad karma working against Ariad. People in a position to do so will make sure that this company stays down, so except for a few dollars to be made on a swing trade, you're not going to realize much profit on this one.

    It's funny and pathetic to see some who post on this board almost wetting themselves with excitement when Ariad makes a 20 or 30 cent move to the upside. Buyout coming!!! they breathlessly intone. What hyperbolic folderol. Harvey Berger is buying more time to enrich himself and his cronies. He put out the 2018 timeframe for profitably, which is a key tipoff that this will remain a moribund stock for the foreseeable future. Believe me there will be another key setback as that time approaches, if the company remains standing until then and I believe it will since Berger has been able to run the scam since 1992.

    What about a buyout? Actually they aren't lining up to take Ariad out. Nobody wants to pay more than $8.00 per share and Harvey won't sell for that.

    But what about the science. The science is AMAZING! Actually it's not. The Ariad scientific team is decidedly inferior to just about any other biotech you can name. While some other biotechs are recent startups yet are progressing rapidly in discovering new molecules and bringing new, innovative drugs to market, Ariad's scientific research team has had 23 years and hasn't done squat. One hopelessly flawed drug with miniscule sales is the best you can do? Of course there's the promise of new AMAZING compounds soon to be announced, but then that has been the story for 23 years. A promise. Unfulfilled.

    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Feb 3, 2015 12:36 PM Flag

    Harvey Berger really" screwed the pooch" when he announced recently that the company had hired its 21st Vice President and that they hoped to achieve profitability by 2018. #$%$! Even old timers like myself couldn't believe the unmitigated gall, the bald faced chicanery on display from the worst, most corrupt CEO in biotech.

    When Ariad announced that they were partnering with Merck on Rida I began to see the real flaws in the company. Harvey Berger was guilty of bald faced lying about the efficacy of the drug which Merck eventually returned to them. Then there was Berger's lies about stint deals and mystery compounds that would turn the oncology world upside down. All lies.

    A couple of other red flags from Berger was when he fired the board of directors and brought in "yes men" to do his bidding. About this time he filed frivolous lawsuit after frivolous lawsuit against the likes of Amgen and Lilly and in each and every case he was defeated in the courtroom after wasting shareholders' hard earned money and keeping the share price suppressed. Harvey Berger has been called the best friend a short seller ever had and that's the truth.


    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Jan 21, 2015 11:24 AM Flag

    It is absolutely incredible, the latest carrot stick hung out by Harvey Berger at the JPM Healthcare Conference. This will supposedly keep the donkey investors plodding on for another 3 years before another carrot stick is proffered by the charlatan. For 25 long years the same tactic has been used and there's never a payoff, just a promise that a payoff is coming just down the road - keep going, keep going. At one time there was going to be a stint deal (never materialized) then Rida was going to be a blockbuster drug (didn't get approved) then Pona was going to be best in class and a blockbuster drug (pulled from market, reentered with anemic sales) now there is the promise of 113 and the god molecule. That should be enough to keep the donkeys plodding for awhile.

    The history of this company is sad and dreary. Hundreds of other biotech companies have rewarded their venture capitalists (investors) with handsome returns that have made some incredibly wealthy. Not ARIAD. This one has enriched Harvey Berger, his henchmen and no one else. Can people be so clueless? Sure many of the posters are pitiful paid pumpers who are trying to eke out a living by making repetitive posts, but a few who post gullible positive comments on the company are naïve retail investors.

    After 25 years of scamming people out of their investment dollars, one can only conclude that the charter of the company is to defraud gullible investors out of their money, or that the scientific team at Ariad is weak - incredibly weak!!!

    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Jan 15, 2015 1:33 PM Flag

    It's titled "You've Been Harvey Bergered" by Ben Dover written for Scam magazine.

    Sentiment: Strong Sell

  • He says he is excited about where they are headed. He's the only one. He's headed for a cliff that will wipe out Ariad investors but of course he won't be in the car when it goes over the cliff. He will be headed for the bank which is what he always does as he soaks the Ariad fan boys.

    A moribund $6.00 stock in 2015 after having incorporated in 1991? Could anyone be any worse? As an example you could have invested in Isis Pharmaceuticals about a year and a half ago when both were trading for around $6.00 per share. Isis is now around $71.00 per share and Ariad? Same old same old.

    Harvey Berger now has 21 Vice Presidents at Ariad. They are all his buddies and he is looking to add another 20 VP's because that is what this company has been about in its 24 miserable years of existence - get rich on the backs of the dupes!

    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Jan 13, 2015 2:20 PM Flag

    It will be made into a salve for the ruptured anuses of Ariad idiot longs. Enjoy!

    Sentiment: Strong Sell

  • Reply to


    by simon_tymplar Dec 23, 2014 3:54 PM
    simon_tymplar simon_tymplar Dec 23, 2014 4:00 PM Flag


    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Dec 23, 2014 3:54 PM Flag

    The devil is in the details....

    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Dec 23, 2014 1:37 PM Flag

    Debuted last year at $17.00 per share, today trading over $80 per share even on a big down day for the bios. Now that's the way to run a biotech company.

  • simon_tymplar by simon_tymplar Dec 23, 2014 12:25 PM Flag

    I absolutely LOVE this company because I LOVE making money and I have acquired expensive tastes. Ariad is by far the most reliable short position in my portfolio but of course not all my positions are short. This morning's action is just the beginning of Ariad's misery. They are quickly running out of money and Dr. Pazdur and others at the FDA look very unfavorably on this company and will make sure they have extra hoops to jump through before allowing them to bring another drug to market. Why? Harvey Berger. He is not liked because of his history of lying and chicanery. In business since 1992 and nothing to show for it except one toxic, low selling drug. Many disillusioned investors who have lost millions of dollars by going long Ariad are forever sickened by the ongoing attempts of the company to bilk new, unsavvy

    I will cover some of my short position and go long for a swing trade at around the $5.95 level.

    Sentiment: Strong Sell

  • simon_tymplar by simon_tymplar Dec 17, 2014 3:56 PM Flag

    It's called swinging her high to swing her low. Best action in town! Make some money boys.

    Sentiment: Strong Sell

  • Reply to

    George Soros Another One Dumping Ariad

    by simon_tymplar Dec 15, 2014 11:05 AM
    simon_tymplar simon_tymplar Dec 15, 2014 12:51 PM Flag

    "Your prejudice is that he loses, and mine, that he wins"

    And that's what makes a ball game to put it in those metaphorical terms.

    The index fund advice is just generic advice as the majority of investors want to own a piece of a company long and only feel comfortable doing that. I, personally would never put most of my money "under the mattress". There are too many money making opportunities in any market, up or down. One good choice now for the intrepid investor would be to open a short or ultra short fund position available through Fidelity for instance.

    Sentiment: Strong Sell

  • Reply to

    Ariad Still WAY Overvalued!!!

    by simon_tymplar Dec 15, 2014 10:49 AM
    simon_tymplar simon_tymplar Dec 15, 2014 12:28 PM Flag

    I absolutely do think it can go that low in the next 6 months. Will it? Who knows, the market is such an irrational place - a few more well placed buyout rumors could keep it from falling to true value, but massive dilution will soon catch up with the share price. Any way you look at it this is a terrible company and a terrible investment. Reminds me of Dendreon, not in terms of product sold, but in terms of corrupt, incompetent management.

    Sentiment: Strong Sell

  • Reply to

    George Soros Another One Dumping Ariad

    by simon_tymplar Dec 15, 2014 11:05 AM
    simon_tymplar simon_tymplar Dec 15, 2014 11:48 AM Flag

    Using Alex Denner as a rationale for buying shares of Ariad Pharmaceuticals would be laughable if not so tragic for the un-savvy retail investor. First of all, Alex Denner is not god. He makes almost as many poor investment decisions as he does good ones. When he took a stake in Vivus Pharmaceuticals it was trading near $10.00 per share. Now it sits at $3.00 and is struggling to survive. When he took the stake in Vivus that message board lit up, like the Ariad board did when he took a stake here. Oh the share price was going to sky rocket, there would be a bidding war on the buyout, blue skies and riches dead ahead, and the share price began to fall.

    Denner wins some and he loses some. His wins allow him to play more hands of poker, which means he will ultimately lose more money at some future point in time. So, scratch Denner as a reason to invest in Ariad. Word on the street is that he will dump and move on soon anyway. He's not in love with Ariad. Why would he be? He's a gambler and will soon use his money to make a more attractive bet.

    I really believe that Ariad will continue to weaken and Harvey Berger, struggling to hold on to his damaged baby as long as he can, will finally be forced to sell at around today's trading price. Anything else projecting a higher sale price is just being a cockeyed optimist.

    If I held Ariad long and sold, I would put my money in a good index based mutual fund and hope and pray that the approaching market downturn will not be too long and too severe.

    Sentiment: Strong Sell

  • Follow the smart money. Salvage what you can from this horrible investment. Better to take a loss and put what you have left with a good company that can help you recover some of your losses. One of the reasons Soros is dumping is as follows:

    Ariad won't be cash flow positive for years.
    Although Ariad's total net revenues and sales of its flagship cancer drug, Iclusig, have been growing by double digits quarter over quarter, the company is still hemorrhaging cash. In the third quarter, Ariad reported that Iclusig net sales increased by 22% to $14.5 million, compared to the second quarter of 2014.

    Unfortunately, the company lost $50.1 million during the quarter due mainly to its extensive clinical trial program aimed at expanding Iclusig's label. With $273 million in cash and cash equivalents remaining at the end of the third quarter, Iclusig sales will therefore have to rocket higher from current levels, or the company will have to cut expenses in a big way, in order to avoid diluting shareholders via a large secondary offering, perhaps within the next six months. While the Street is expecting Ariad to narrow its loss per share next year by 32%, this still won't be enough to spare shareholders from a capital raise.

    Sentiment: Strong Sell

8.13+0.01(+0.12%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.